Therefore, tumors with BRAF or KRAS mutations were in correlation with elevated serum level of tumor biomarkers of CRC and the association of tumor biomarkers and molecular status may indicate the poor prognosis of these patients. This evidence concerns the gene BRAF and neoplasm.